---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250656"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:13:43.985827+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide

## Summary
- NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.
- Combination with high-dose semaglutide achieved up to 26% weight loss, best-in-class vs. NLRP3 inhibitors.
- Preclinical data support potential as oral, brain-penetrant NLRP3 inhibitor for obesity.
- Neumora plans to initiate Phase 1 clinical study for NMRA-215 in Q1 2026.
- Additional data to be presented at virtual R&D day on October 27, 2025.

## SEC filing metadata
- accession: 0001193125-25-250656
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525250656/0001193125-25-250656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525250656/nmra-20251027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250656
- JSON: https://secwatch.observer/filing/0001193125-25-250656.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.